Article Text

Download PDFPDF

P601 Macrolide and fluoroquinolone resistance-associated mutations in mycoplasma genitalium: a systematic review and meta-analysis
  1. Dorothy Machalek1,
  2. Yusha Tao2,
  3. Hannah Shilling1,
  4. Jorgen Jensen3,
  5. Magnus Unemo4,
  6. Gerald Murray1,
  7. Eric Chow2,
  8. Nicola Low5,
  9. Suzanne Garland1,
  10. Christopher Fairley2,
  11. Lenka Vodstrcil2,
  12. Jane Hocking6,
  13. Lei Zhang2,
  14. Catriona Bradshaw2
  1. 1The Royal Women’s Hospital, Centre for Women’s Infectious Disease Research, Parkville, Australia
  2. 2Alfred Health, Melbourne Sexual Health Centre, Carlton, Australia
  3. 3Statens Serum Institut, Research Unit for Reproductive Microbiology, Copenhagen, Denmark
  4. 4Örebro University, WHO Collaborating Centre for Gonorrhoea and Other STIs, Department Of Laboratory Medicine, Faculty of Medicine and Health, Örebro, Sweden
  5. 5Institute of Social and Preventive Medicine (ISPM), Bern, Switzerland
  6. 6University of Melbourne, Melbourne School of Population and Global Health, Parkville, Australia


Background Treatment for Mycoplasma genitalium is becoming increasingly complicated by antimicrobial resistance. We summarised published global data on the prevalence of macrolide and fluoroquinolone resistance-associated mutations in M. genitalium and examined trends over time.

Methods We searched PubMed, EMBASE and Medline until December 31, 2017. We included studies that reported the percentage of key mutations associated with macrolide resistance (23S rRNA gene: A2071C/G/T; A2072C/G/T) and/or fluoroquinolone failure (parC gene: S83R/I; D87N/Y) among M. genitalium positive specimens. Data were extracted by geographic region, collection year, sex, and risk group (men who have sex with men [MSM] or heterosexual). Summary estimates (95% confidence intervals [CI]) were calculated using random-effects meta-analyses. Subgroup and meta-regression analyses were conducted to assess heterogeneity.

Results 47 studies met the inclusion criteria reporting resistance-associated mutations for macrolides (n=45) and fluoroquinolones (n=18). Global prevalence of macrolide resistance mutations increased from 4.9% [95% CI 0.0–15.7%] before 2009, to 46.3% [30.7–62.2%] in 2016–17 (p-trend=0.001). This increase was greatest in the Western Pacific region (Australia in particular) where prevalence increased from 12.6% [2.6–26.9%] to 69.2% [60.7–77.1%] (p-trend<0.001). Prevalence of macrolide resistance-associated mutations was also higher among MSM (72.3% [58.6–84.5%]) than heterosexual men (37.3% [25.8–49.6%]) (p<0.001). Global prevalence of fluoroquinolone resistance mutations was 6.3% [4.2–8.9%] with no changes over time or by risk group, but regional variations were present with highest prevalence in the Western Pacific region (14.9% [9.7–20.9%]) and North America (11.2% [2.9–23.3%]), and lowest in Europe (2.8% [1.7–4.1%]). Dual class resistance mutation prevalence was 2.5% [1.1–4.2%] with no change over time or by risk group. Regional variations were similar to those for fluoroquinolone resistance mutations.

Conclusion Resistance to recommended first and second line treatments for M. genitalium is a growing public health problem. Global surveillance and antimicrobial resistance-guided therapies are needed to inform more effective regional strategies for the control and treatment of M. genitalium.

Disclosure No significant relationships.

  • Mycoplasma genitalium
  • antimicrobial resistance
  • meta-analysis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.